Collaborating Countries
IIBDGC >16 Collaborating Countries

Groups involved

Contact details of the individual groups are listed below. Please direct International IBD Genetics Consortium enquiries to enquiries@ibdgenetics.org

UKIBDGC

The UK IBD Genetics Consortium (http://www.ibdresearch.co.uk/) is an open group consisting of a number of clinical centres and the Wellcome Trust Sanger Centre (Analysts : Jeff Barrett and Carl Anderson). We have presently recruited over 10,000 patients with Crohn's disease and ulcerative colitis into our genetics studies. GWAS have been performed in Crohn's disease as part of the original Wellcome Trust Case Control Consortium (WTCCC) experiment and in ulcerative colitis as part of WTCCC2. Please contact UKIBDGC at UKIBDGC_enquiries@sanger.ac.uk

New centres for 2011 include:

NIDDK

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) was created in 2002 by the National Institute of Diabetes, Digestive and Kidney diseases (NIDDK); to advance knowledge on the inflammatory bowel diseases, specifically Crohn's Disease and Ulcerative Colitis.

The NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) consists of six genetic research centers (GRC) and a data coordinating center (DCC). The IBDGC is involved with independent genetic research studies and actively works with a variety of members from the broader IBD and genetics communities on collaborative projects.

The NIDDK IBDGC Principal Investigators are:

For further information please refer to the The NIDDK Inflammatory Bowel Disease Genetics Consortium's webpage

France

The French UC patients have been diagnosed, recruited and followed up at the University Hospital of Lille and Nancy. The principal investigators from this group are :

Sweden

Swedish team:

Netherlands

The Dutch initiative on Crohn and colitis (ICC) is a nationwide collaborative effort from all eight university medical centers in the Netherlands studying the inflammatory bowel diseases.

PI ICC-Genetics: R.K.Weersma, MD PhD Gastroenterologist Department of Gastroenterology and Hepatology University Medical Center Groningen PO Box 30.001 9700RB Groningen the Netherlands T: +31503610426 F: +31503619306 r.k.weersma@mdl.umcg.nl

http://www.initiativeoncrohnandcolitis.nl/

Germany

Site: Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, Germany & 1st Medical Department of the University Hospital S.-H., Campus Kiel

Principle Investigators:

Analytical Team:

www.ikmb.uni-kiel.de & www.popgen.de

Belgium

Belgian IBD Genetics Consortium consists of: (alphabetical order of centres) - first name for each centre is the PI

Italy

The Italian IBD cohort is an hospital-based population, collected in tertiary referral centers.

The PI of the Italian cohort is Vito Annese vito.annese@tin.it, Head of Gastroenterology at the University Hospital Careggi of Florence

The principal investigators of different sites are:

Australia and New Zealand Inflammatory Bowel Disease Consortium (ANZIBDC)

The ANZIBDC was formed in 2008 and currently consists of ten Gastroenterology centres throughout Australia and New Zealand. The major objective of this Consortium is to progress knowledge and clinical practice in the field of IBD through the combination of both clinical and scientific research, thus improving patient outcomes across the Australian and New Zealand populations.

The main goals pursued by the Consortium in order to achieve its objectives are:

For more information on ANZIBDC and its projects, please visit http://ibd.qimr.edu.au/anzibdc.html or contact ANZIBDC Project Officer Krupa Krishnaprasad krupak@qimr.edu.au.

Under the auspices of the Australian and New Zealand IBD Consortium, the following Australian IBD centres have contributed to the International IBD Genetics Consortium studies:

Brisbane, Queensland, Australia

A/Prof Graham Radford-Smith

The Brisbane Inflammatory Bowel Disease Research Group consists of clinicians and scientists from the Royal Brisbane and Women's Hospital and the Queensland Institute of Medical Research (QIMR). Studies involve a specialist-based cohort of patients managed at the Royal Brisbane and Women's Hospital, a population-based cohort of patients from the North Brisbane community (total population 732,000), and non-IBD controls drawn from the same population.

QIMR, being the central hub for the ANZIBDC, has taken a lead role in the development of the ANZIBDC and continues to play a major role in the management of data and samples for the consortium.

Contacts:

Website:

Brisbane, Queensland, Australia

Prof Tim Florin

The Mater Health Services' IBD comprises a hospital-based IBD cohort in Brisbane. The principal investigators from this group are Prof Tim Florin, Dr Marianne Mortimore and Associate Professor Michael McGuckin.

Contacts:

Website:

Fremantle, Western Australia

Prof Ian Lawrance

The Centre for Inflammatory Bowel Diseases, Fremantle Hospital is a specialist centre that currently manages over 1000 IBD patients. The principal investigator is Prof Ian C Lawrance from the School of Medicine and Pharmacology, University of Western Australia.

Contacts

South Adelaide, South Australia

A/Prof Peter Bampton

The Southern Adelaide IBD Service is based in the southern suburbs of Adelaide and drains country patients from the southern aspect of South Australia, representing a population of approximately 400,000. The principal investigator from this group is A/Prof Peter Bampton, from the Department of Gastroenterology and Hepatology, Flinders Medical Centre.

Contacts

Adelaide, South Australia

A/Prof Jane Andrews

The Royal Adelaide Hospital (RAH) IBD Service is based centrally in the city of Adelaide. The Service caters directly for a population of ~600,000 locally and many more by referral in from rural and regional South Australia. We currently care for over 500 IBD patients. Our unit has a particular interest in clinical care models, optimising the use of standard care, psychological and social issues in IBD and outreach care to IBD patients in remote locations. A/Prof Jane Andrews is the Head of the Service with Dr David Hetzel playing an active role in coordinating the unit's sponsored clinical trials. The unit is within the Department of Gastroenterology & Hepatology and linked also to the School of Medicine at the University of Adelaide.

Contacts

Townsville, Queensland, Australia

Dr Gillian Mahy (Director of Medicine, Townsville Hospital, Queensland)

The Townsville Hospital IBD Service is based in regional North Queensland and covers an urban and rural population of some 250,000 with an additional rural and remote population draining from central and central north Queensland and Torres Strait Islands. The principal investigator is Dr Gillian Mahy assisted by research nurse Sharon Cooke. The unit resides within the Department of Gastroenterology and Hepatology and is linked with the School of Medicine, James Cook University.

Contacts

New Zealand

The Canterbury IBD Cohort is a population-based IBD cohort comprising 92% of IBD patients (1420) from the Canterbury region of New Zealnad (population ~500,000). The principal investigators from this group are A/Prof Richard Gearry, Dr Rebecca Roberts and Clinical Professor Murray Barclay from the Department of Medicine, University of Otago, Christchurch.

Contacts

Cookies policy | Terms and Conditions. This site is hosted by the Wellcome Trust Sanger Institute.